Your browser is no longer supported. Please, upgrade your browser.
PSTI Pluristem Therapeutics Inc. daily Stock Chart
Pluristem Therapeutics Inc.
Index- P/E- EPS (ttm)-0.24 Insider Own2.20% Shs Outstand111.65M Perf Week-3.60%
Market Cap149.61M Forward P/E- EPS next Y-0.39 Insider Trans-2.76% Shs Float103.16M Perf Month8.06%
Income-24.20M PEG- EPS next Q-0.06 Inst Own4.00% Short Float1.82% Perf Quarter-2.19%
Sales0.05M P/S2992.22 EPS this Y-8.90% Inst Trans-4.06% Short Ratio5.10 Perf Half Y-13.55%
Book/sh0.30 P/B4.47 EPS next Y-9.10% ROA-61.90% Target Price3.83 Perf Year-4.29%
Cash/sh0.05 P/C25.36 EPS next 5Y- ROE-77.40% 52W Range1.06 - 2.12 Perf YTD-2.90%
Dividend- P/FCF- EPS past 5Y1.10% ROI- 52W High-36.79% Beta0.31
Dividend %- Quick Ratio4.60 Sales past 5Y- Gross Margin- 52W Low26.42% ATR0.06
Employees175 Current Ratio4.60 Sales Q/Q- Oper. Margin- RSI (14)48.87 Volatility4.27% 4.44%
OptionableYes Debt/Eq0.00 EPS Q/Q83.80% Profit Margin- Rel Volume0.37 Prev Close1.30
ShortableYes LT Debt/Eq0.00 EarningsFeb 28 Payout- Avg Volume367.23K Price1.34
Recom2.00 SMA20-1.80% SMA500.95% SMA200-5.79% Volume137,079 Change3.08%
Feb-13-17Downgrade Maxim Group Buy → Hold
Jul-19-16Resumed H.C. Wainwright Buy $3.50
Dec-22-15Reiterated Maxim Group Buy $8 → $3
Feb-03-15Reiterated Needham Buy $5 → $4
Sep-22-14Resumed Oppenheimer Outperform
Sep-08-14Initiated H.C. Wainwright Buy $4
Jan-21-14Reiterated MLV & Co Buy $4.50 → $6
Sep-16-13Upgrade Maxim Group Hold → Buy $8
Jun-04-13Downgrade Maxim Group Buy → Hold
May-31-13Initiated MLV & Co Buy $4.50
Jul-25-12Initiated Maxim Group Buy $8
Jul-24-12Downgrade WBB Securities Speculative Buy → Hold $4 → $3.75
May-22-12Initiated Needham Buy $5
Dec-09-11Initiated Global Hunter Securities Speculative Buy $5
Jun-17-11Initiated Dawson James Buy $5
May-17-11Initiated Oppenheimer Outperform $5
Mar-01-11Initiated WBB Securities Speculative Buy $4
Jan-10-11Initiated National Securities Buy
May-16-18 04:43PM  Pluristem Therapeutics Inc (NASDAQ:PSTI): Are Analysts Optimistic? Simply Wall St.
May-10-18 08:01AM  Pluristem: Fiscal 3Q Earnings Snapshot Associated Press
07:00AM  Pluristem Reports Third Quarter Fiscal 2018 Corporate and Financial Highlights GlobeNewswire
Apr-30-18 02:46PM  FDA Clears New Drug Application For Pluristem's PLX-R18; What's Next? Benzinga +6.45%
08:41AM  Benzinga Pro's 6 Stocks To Watch Today Benzinga
07:00AM  U.S. FDA Clears Pluristems IND to Treat Victims Exposed to Acute Radiation GlobeNewswire
07:00AM  FDA clears Pluristem radiation treatment for emergency use Reuters
Apr-25-18 08:46AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
07:00AM  U.S. FDA Clears Pluristems Phase III Study in Treatment of Muscle Injury Following Hip Fracture Surgery GlobeNewswire
Apr-23-18 07:00AM  Pluristem and Indiana University to Initiate Joint Project Evaluating PLX-R18 in Acute Radiation Syndrome, Targeting Bridging Data for Pivotal Study GlobeNewswire
Mar-26-18 07:00AM  Roger Jeffs, Former Co-CEO of United Therapeutics, Joins Pluristem's Strategic Advisory Board GlobeNewswire
Feb-27-18 07:00AM  Pluristems PLX-R18 Improves Hematopoietic Transplantation as Reported in Scientific Journal Frontiers in Medicine GlobeNewswire +5.84%
Feb-15-18 08:47PM  What You Must Know About Pluristem Therapeutics Incs (NASDAQ:PSTI) Major Investors Simply Wall St.
Feb-07-18 07:44AM  Pluristem Issues Letter to Shareholders GlobeNewswire
Jan-31-18 02:12PM  N.Korea threats spur U.S. search for new radiation therapies Reuters
Jan-17-18 07:30AM  Wired News Pluristems PLX Cells Demonstrated Inhibition of Cancer Cell Growth in Peer-Reviewed Article ACCESSWIRE
Jan-12-18 07:00AM  Pluristems PLX Cells Significantly Inhibit Cancer Cell Growth in Newly Published Study GlobeNewswire +5.92%
Jan-09-18 07:00AM  FDA Clears Pluristems Expanded Access Program to Initiate Treatments of Critical Limb Ischemia Outside of Ongoing Phase III Study GlobeNewswire +8.84%
Dec-25-17 11:55AM  Does Pluristem Therapeutics Incs (NASDAQ:PSTI) Past Performance Indicate A Weaker Future? Simply Wall St.
Dec-12-17 07:30AM  Wired News VistaGen Receives US Patent on Methods for Producing Blood Cells, Platelets, and Bone Marrow Stem Cells ACCESSWIRE
05:30AM  Pluristem Granted Manufacturer Authorization and Good Manufacturing Practice (GMP) Certification by Israels Ministry of Health, Supporting Pivotal-Stage Studies GlobeNewswire
Dec-07-17 05:08AM  Pluristem to Present Data on PLX-R18 in Treatment of Acute Radiation Syndrome at American Society of Hematologys Annual Meeting GlobeNewswire
Nov-29-17 07:00AM  Peer-Reviewed Article Published on Pluristems PLX-PAD Cells Mechanism of Action to Restore Blood Flow in Ischemic Tissue GlobeNewswire
Nov-22-17 07:00AM  Pluristem Granted Key U.S. Patent for Skeletal Muscle Regeneration - a Meaningful Asset Ahead of Upcoming Phase III Femoral Neck Fracture Study GlobeNewswire
Nov-14-17 07:00AM  Pluristem Reports First Quarter Fiscal 2018 Corporate and Financial Highlights GlobeNewswire
Nov-13-17 06:05AM  Is It Time To Buy Pluristem Therapeutics Inc (PSTI)? Simply Wall St.
Nov-08-17 03:59PM  Pluristem reports 1Q loss Associated Press
Nov-06-17 07:00AM  Pluristem Enters into Agreement with Tel Aviv Sourasky Medical Center to Conduct Phase I/II Trial in Steroid-Refractory Chronic GvHD GlobeNewswire
Oct-30-17 02:45PM  Pluristem Announces Pricing of Public Offering of Common Stock on the Tel Aviv Stock Exchange GlobeNewswire -14.72%
Oct-29-17 05:49PM  Pluristem Proposes to Launch a Public Offering of Common Stock on the Tel Aviv Stock Exchange After Concluding an Israeli Institutional Investors Tender GlobeNewswire
Oct-26-17 07:00AM  Following Approval of Israels Ministry of Health, Pluristem Extends its Trial of PLX-R18 to Treat Insufficient Hematopoietic Recovery after Bone Marrow Transplant and Opens Clinical Centers in Israel GlobeNewswire
Oct-23-17 07:00AM  Pluristem Expands its Reach in the Treatment of Impaired Hematopoietic Systems with a European Patent Covering PLX-R18 in Chemotherapy, ARS, Genetic Disorders and Autoimmune Diseases GlobeNewswire
Oct-19-17 07:30AM  FDA Grants Pluristem Orphan Drug Designation for Its PLX-R18 Cell Therapy as Treatment for Acute Radiation Syndrome GlobeNewswire
Oct-16-17 07:00AM  New Published Data Highlights the Potential of Pluristem's PLX Cells in Improving Cardiac Function in Diabetes GlobeNewswire
Oct-12-17 08:00AM  Today's Research Reports on Trending Tickers: Athersys and Pluristem Therapeutics ACCESSWIRE
Oct-11-17 08:47AM  Pluristem Therapeutics Inc. (PSTI) Catches Eye: Stock Jumps 5.1% Zacks +15.24%
Oct-02-17 07:00AM  $7.9 Million Granted to nTRACK Collaborative Project Designed to Study Pluristems PLX-PAD Cells GlobeNewswire
Sep-29-17 07:00AM  Earnings Review and Free Research Report: Pluristem Announced Fiscal 2017 Results ACCESSWIRE
Sep-26-17 07:00AM  Pluristem Receives Positive Feedback from FDA and EMA as Company Prepares for Phase III Trial of PLX-PAD to Support Recovery from Hip Fracture GlobeNewswire
Sep-20-17 07:10AM  Corporate News Blog - Nabriva Therapeutics Declares Positive Top-line Results from Phase-3 Clinical Trial Evaluating Lefamulin for the Treatment of CABP ACCESSWIRE +6.85%
Sep-19-17 10:35AM  Pluristem's Ischemia Candidate Gets Fast Track Designation Zacks
Sep-18-17 10:30AM  Biotech Stocks Surging in September ACCESSWIRE +5.97%
10:15AM  Pluristem Wins Key FDA Approval 24/7 Wall St.
08:07AM  UPDATE: Pluristem stock jumps 21% premarket after FDA grants CLI treatment fast-track designation MarketWatch
07:00AM  U.S. FDA Grants Fast Track Designation to Pluristem's PLX-PAD for the Treatment of Critical Limb Ischemia (CLI) GlobeNewswire
Sep-13-17 07:00AM  Pluristem Strengthens Its Position in Asia, Awarded Two New Patents in Hong Kong for Critical Limb Ischemia and Muscle Regeneration GlobeNewswire +9.76%
Sep-11-17 08:17AM  Pluristem Reports Fourth Quarter and Fiscal 2017 Corporate and Financial Highlights GlobeNewswire +9.40%
06:51AM  Should You Buy Pluristem Therapeutics Inc (PSTI)? Simply Wall St.
Sep-05-17 07:00AM  $8.7 Million Awarded to Support Phase III Femoral Neck Fracture Trial by EU Horizon 2020 Program GlobeNewswire
Aug-17-17 08:00AM  Today's Research Reports on Stocks to Watch: Teva Pharmaceutical and Pluristem Therapeutics ACCESSWIRE
Aug-16-17 03:23PM  These Are the Hottest Stocks on the Planet Wednesday: URBN, TGT, PSTI, CSCO +5.31%
09:45AM  Biotech Movers: Disappointment for Bristol-Myers Kidney Combo Boosts Exelixis
07:30AM  U.S. Department of Defense to Conduct Studies of Pluristems PLX-R18 in a New ARS Project for Use Before Radiation Exposure GlobeNewswire
Aug-09-17 07:00AM  Israeli Government to Support Pluristems Marketing Activity in China Ministry of Economy Awards Company Smart Money Grant GlobeNewswire
Jul-27-17 08:00AM  Today's Research Reports on Trending Tickers: Biogen Inc. and Pluristem Therapeutics Inc. ACCESSWIRE
Jul-26-17 03:09PM  Pluristem stock rises 2.5% on mid-stage clinical trial results MarketWatch
01:00PM  New Data from ARS Study Shows Significant Hematological Deficiencies Even at Low Radiation Levels; PLX-R18 Supports Hematological Recovery GlobeNewswire
Jul-18-17 07:16AM  This new drug could help the U.S. survive a nuclear meltdown MarketWatch
Jul-10-17 07:00AM  Pluristem Advances its Multinational Phase III Critical Limb Ischemia Study, Targeting Initiation at 40 Active Sites by the End of 2017 GlobeNewswire
Jun-29-17 07:00AM  Pluristem to Present New Data from ARS study at Radiology Conference in U.S. GlobeNewswire
May-22-17 07:30AM  Pluristem Provides Shareholder Update on Corporate and Clinical Developments GlobeNewswire +8.46%
May-10-17 08:00AM  Today's Research Reports on Corbus Pharmaceuticals and Pluristem Therapeutics Post Earnings Accesswire
May-09-17 05:46AM  Pluristem reports 3Q loss Associated Press
May-03-17 07:00AM  Pluristem Announces Promising Results from Non-Human Primate Pilot Study of PLX-R18 in Acute Radiation Syndrome GlobeNewswire
Apr-19-17 08:01AM  Pluristem Reaches Milestone of 100 Granted Patents, Including Coverage of Leading Indications in Major Markets GlobeNewswire
Apr-06-17 09:31AM  Pluristem Therapeutics (PSTI) Shares March Higher, Can It Continue? Zacks
Apr-05-17 08:30AM  Onconova Therapeutics and Pluristem Therapeutics Surge as Candidate Drugs Move Closer to Final Approval Accesswire
Apr-03-17 08:00AM  $54 Billion Boost in U.S. Defense Budget Comes as Pluristem's Radiation Antidote Nears FDA Approval Accesswire +9.76%
Mar-30-17 04:21PM  PLURISTEM THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
04:00PM  Pluristem and Sosei CVC Advancing Towards Finalizing Joint Venture for the Commercialization of PLX-PAD in Japan GlobeNewswire
Mar-29-17 04:14PM  PLURISTEM THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to Articles of I
04:00PM  Pluristem Launches Co-CEO Structure and Appoints New CFO GlobeNewswire
Feb-22-17 11:53AM  Pluristem Therapeutics, Inc. :PSTI-US: Earnings Analysis: Q2, 2017 By the Numbers Capital Cube
Feb-14-17 01:04PM  PLURISTEM THERAPEUTICS INC Financials
Feb-13-17 11:59AM  Pluristem Therapeutics downgraded by Maxim Group
07:00AM  Pluristem Reports Second Quarter Fiscal 2017 Highlights & Provides Calendar 2017 Outlook GlobeNewswire
Feb-09-17 05:01AM  Pluristem reports 2Q loss Associated Press
Feb-08-17 04:08PM  PLURISTEM THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report
Jan-25-17 04:30PM  Pluristem Announces Closing of Bought Offering and Underwriters Exercise in Full of Over-Allotment Option GlobeNewswire
Jan-20-17 04:34PM  PLURISTEM THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E -17.86%
07:00AM  Pluristem Increases Previously Announced Bought Deal Offering of Common Stock and Warrants to $15,000,000 GlobeNewswire
Jan-19-17 04:53PM  Pluristem Announces Bought Deal Offering GlobeNewswire
Jan-17-17 02:24PM  Flood of News Presents Buying Opportunity
11:03AM  PLURISTEM THERAPEUTICS INC Files SEC form 8-K, Other Events
05:30AM  Pluristem Receives Clearance from Germany to Initiate its Multinational Phase III Trial in Critical Limb Ischemia Targeting Early Conditional Marketing Approval GlobeNewswire
Jan-13-17 07:09AM  Pluristem (PSTI) Intermittent Claudication Study Enrolled
Jan-12-17 06:00AM  Pluristem Completes Patient Enrollment in a Large Multinational Phase II Trial in Intermittent Claudication GlobeNewswire
02:00AM  Pluristem Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : PSTI-US : January 12, 2017
Jan-11-17 02:31PM  Pluristem Therapeutics Inc. (PSTI) To Begin CLI Phase III Trial Enrolling Only 250 Patients, With FDA Blessing at Insider Monkey
11:02AM  PLURISTEM THERAPEUTICS INC Files SEC form 8-K, Other Events
Jan-10-17 07:18AM  Pluristem shares jump 5.4% premarket as FDA approves trial of treatment for critical limb ischemia at MarketWatch +10.20%
07:00AM  Pluristems Phase III Study of PLX-PAD Cells for the Treatment of Critical Limb Ischemia Cleared by U.S. FDA GlobeNewswire
Dec-29-16 04:09PM  [$$] Mesoblast May Have an Edge on Pluristem at
Dec-27-16 03:00AM  Pluristem and New York Blood Center to Collaborate in Evaluating PLX-R18 as an Adjuvant Therapy to Umbilical Cord Blood Transplantation, Winning $900,000 Funding From BIRD GlobeNewswire
Dec-23-16 06:47AM  PLURISTEM THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
04:00AM  Pluristem and Innovative Medical Management Co., Ltd. Mutually Agree to Extend the Time to Execute the Definitive Investment Agreements Due to New Chinese Monetary Policy GlobeNewswire
Dec-22-16 09:39AM  Pluristem Therapeutics, Inc. Value Analysis (NASDAQ:PSTI) : December 22, 2016
Dec-21-16 02:01AM  Pluristem Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : PSTI-US : December 21, 2016
Dec-20-16 12:04PM  PLURISTEM THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement
01:30AM  Pluristem and Sosei CVC to Establish a New Corporation for the Commercialization of PLX-PAD in Japan GlobeNewswire
Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops PLacental eXpanded (PLX) cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients ineligible for revascularization, recovery after surgery for femoral neck fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases. It also develops PLX-R18 cells that is in Phase I clinical trial for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various in-vivo studies for the evaluation of PLX-R18 for the treatment of ARS. The company has collaborative research agreement with the Berlin-Brandenburg Center for Regenerative Therapies; and a license and commercialization agreement for conducting clinical trials and commercialization of its PLX-PAD product in South Korea related to the treatment CLI and intermediate claudication. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GERMAIN MARKDirectorMar 16Sale1.4811,64017,227513,944Mar 19 05:08 PM
GERMAIN MARKDirectorMar 15Sale1.4834,23350,665525,584Mar 19 05:08 PM
GERMAIN MARKDirectorMar 14Sale1.5023,81835,727559,817Mar 15 05:12 PM